CU20200070A7 - Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de quinasa dependientes de ciclina - Google Patents
Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de quinasa dependientes de ciclinaInfo
- Publication number
- CU20200070A7 CU20200070A7 CU2020000070A CU20200070A CU20200070A7 CU 20200070 A7 CU20200070 A7 CU 20200070A7 CU 2020000070 A CU2020000070 A CU 2020000070A CU 20200070 A CU20200070 A CU 20200070A CU 20200070 A7 CU20200070 A7 CU 20200070A7
- Authority
- CU
- Cuba
- Prior art keywords
- amino
- pyridine
- kinase inhibitors
- dependent kinase
- cycline
- Prior art date
Links
- 150000003930 2-aminopyridines Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 title 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical group NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 abstract 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Abstract
<p>Esta invención se relaciona con compuestos derivados de 2-amino-piridina o 2-amino-piridina sustituidos como inhibidores de cinasa dependiente de ciclina de acuerdo a la fórmula (I)</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>O una sal farmacéuticamente aceptable del mismo, en la cual los grupos-R R¹ a R²³, A, Q, U, V, W, X, Y, Z, n, p y q son como se definen en la presente, con composiciones farmacéuticas que comprenden tales compuestos y sales, útiles para el tratamiento de crecimiento celular anormal, que incluye cáncer, en un sujeto.</p>
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663096P | 2018-04-26 | 2018-04-26 | |
| US201862750454P | 2018-10-25 | 2018-10-25 | |
| US201962826609P | 2019-03-29 | 2019-03-29 | |
| PCT/IB2019/053314 WO2019207463A1 (en) | 2018-04-26 | 2019-04-22 | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20200070A7 true CU20200070A7 (es) | 2021-05-12 |
Family
ID=66676856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2020000070A CU20200070A7 (es) | 2018-04-26 | 2019-04-22 | Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de quinasa dependientes de ciclina |
Country Status (40)
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR109596A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos pirazolopiridina y sus usos |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| DK3755703T3 (da) | 2018-02-20 | 2022-06-27 | Incyte Corp | N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| CN118286225A (zh) * | 2018-04-26 | 2024-07-05 | 辉瑞公司 | 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| CN111655295B (zh) | 2018-08-29 | 2024-05-28 | 荣昌生物制药(烟台)股份有限公司 | 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
| WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| CN110535628B (zh) | 2019-08-29 | 2020-07-17 | 阿里巴巴集团控股有限公司 | 通过证书签发进行多方安全计算的方法及装置 |
| CR20220170A (es) | 2019-10-11 | 2022-10-10 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| PT4181920T (pt) | 2020-07-15 | 2025-11-04 | Ctxt Pty Ltd | Inibidor de kat6 e combinações para o tratamento do cancro da mama |
| CN116322693A (zh) * | 2020-08-13 | 2023-06-23 | 辉瑞公司 | 组合疗法 |
| CN112028834B (zh) * | 2020-09-11 | 2022-03-29 | 济南悟通生物科技有限公司 | 一种阿贝西利的中间体的合成方法 |
| MX2023003054A (es) * | 2020-09-15 | 2023-04-05 | Pfizer | Formas solidas de un inhibidor de cdk4. |
| CN112679522B (zh) * | 2020-12-29 | 2023-02-14 | 南京正济医药研究有限公司 | 一种巴洛沙韦中间体的制备方法 |
| WO2022149057A1 (en) * | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| CN120682245A (zh) | 2021-02-03 | 2025-09-23 | 江苏恒瑞医药股份有限公司 | 稠三环类细胞周期蛋白-依赖性激酶抑制剂及其制备方法和医药用途 |
| US20240269073A1 (en) * | 2021-06-07 | 2024-08-15 | Zerion Pharma ApS | Co-amorphous forms for use in cancer therapy |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| AU2022400308B2 (en) * | 2021-12-02 | 2026-02-12 | Pfizer Inc. | Cdk4 inhibitor for the treatment of cancer |
| EP4440575A1 (en) * | 2021-12-02 | 2024-10-09 | Pfizer Inc. | Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN118339157A (zh) * | 2021-12-24 | 2024-07-12 | 江苏恒瑞医药股份有限公司 | 氢化吲哚类化合物、其制备方法及其在医药上的应用 |
| AU2023212957A1 (en) * | 2022-01-25 | 2024-08-22 | Kinnate Biopharma Inc. | Inhibitors of cdk4/6 kinase |
| US12275738B2 (en) | 2022-04-08 | 2025-04-15 | Biolexis Therapeutics, Inc. | CDK9 inhibitors |
| JP2025511975A (ja) * | 2022-04-08 | 2025-04-16 | バイオレクシス セラピューティクス，インコーポレイティド | Ｃｄｋ９阻害剤 |
| IL316556A (en) * | 2022-04-29 | 2024-12-01 | Beigene Ltd | 6-(Pyrimidine-4-yl)quinoline compounds are being developed as cyclin-dependent kinase inhibitors. |
| WO2023208172A1 (en) * | 2022-04-29 | 2023-11-02 | Beigene , Ltd. | Substituted 7- (pyrimidin-4-yl) quinolin-4 (1h) -one compounds as cyclin dependent kinase inhibitors |
| CN119630652A (zh) * | 2022-07-29 | 2025-03-14 | 安锐生物医药公司 | 氨基杂芳基激酶抑制剂 |
| JP2025533719A (ja) | 2022-07-29 | 2025-10-09 | ファイザー・インク | がんの治療のためのｋａｔ６阻害剤を含む投与レジメン |
| WO2024027631A1 (zh) | 2022-08-01 | 2024-02-08 | 江苏恒瑞医药股份有限公司 | 一种稠三环类衍生物的晶型及制备方法 |
| KR20250054814A (ko) * | 2022-09-05 | 2025-04-23 | 티와이케이 메디슨즈, 인코포레이티드 | Cdk4 키나아제 억제제로 사용되는 화합물 및 이의 용도 |
| WO2024066986A1 (zh) * | 2022-09-30 | 2024-04-04 | 楚浦创制（武汉）医药科技有限公司 | 2-氨基嘧啶类化合物及其应用、药用组合物 |
| KR20250164842A (ko) | 2023-03-30 | 2025-11-25 | 화이자 인코포레이티드 | Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법 |
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| WO2024220866A1 (en) * | 2023-04-19 | 2024-10-24 | Accutar Biotechnology Inc. | Novel aminopyrimidine derivatives as cyclin-dependent kinase inhibitors |
| EP4719405A1 (en) | 2023-06-02 | 2026-04-08 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
| JP2026519559A (ja) | 2023-06-02 | 2026-06-16 | ファイザー・インク | エストロゲン受容体分解薬およびｃｄｋ４阻害剤の組合せ |
| CN120936609A (zh) * | 2023-07-19 | 2025-11-11 | 浙江同源康医药股份有限公司 | 用作cdk2/4蛋白激酶抑制剂的化合物及其应用 |
| TW202513069A (zh) | 2023-07-21 | 2025-04-01 | 美商冰洲石生物科技公司 | 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物 |
| EP4775575A1 (en) * | 2023-09-05 | 2026-07-15 | TYK Medicines, Inc. | Compound used as cdk4 kinase inhibitor and use thereof |
| EP4791727A1 (en) * | 2023-10-11 | 2026-08-19 | Beone Medicines I GmbH | Substituted 6-(pyrimidin-4-yl)quinoline compounds as cyclin dependent kinase inhibitors |
| WO2025104624A1 (en) | 2023-11-14 | 2025-05-22 | Pfizer Inc. | Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol |
| WO2025141469A1 (en) | 2023-12-26 | 2025-07-03 | Pfizer Inc. | Crystalline form of 2-methoxy-n-{4-methoxy-6-[(1h-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide |
| WO2025157245A1 (en) * | 2024-01-25 | 2025-07-31 | Allorion Therapeutics Inc | Aminoheteroaryl kinase inhibitors |
| WO2025183591A1 (ru) * | 2024-02-29 | 2025-09-04 | Федеральное государственное унитарное предприятие "Всероссийский научно-исследовательский институт автоматики им. Н.Л. Духова" (ФГУП "ВНИИА") | Производные 2н-[1,4]оксазино- и 2h-[1, 4]тиазино[3,2-c]хинолин-3(4h)-онов в качестве ингибиторов атм и dna-pk киназ |
| TW202539674A (zh) * | 2024-03-05 | 2025-10-16 | 大陸商浙江同源康醫藥股份有限公司 | 用作cdk4蛋白激酶抑制劑的化合物及其應用 |
| WO2025202871A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor |
| WO2025202900A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors for use in the treatment of mantle cell lymphoma |
| WO2025202854A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
| CN118440041B (zh) * | 2024-07-02 | 2024-09-27 | 苏州凯瑞医药科技有限公司 | 一种手性4-氨基-3-羟基四氢吡喃的制备方法 |
| WO2026025013A2 (en) | 2024-07-26 | 2026-01-29 | Pfizer Inc. | Combination therapy using cdk4 inhibitors for cancer treatments |
| TW202611038A (zh) * | 2024-09-04 | 2026-03-16 | 大陸商浙江同源康醫藥股份有限公司 | 用作cdk4蛋白激酶抑制劑的化合物及其應用 |
| WO2026133192A1 (en) | 2024-12-20 | 2026-06-25 | Pfizer Inc. | Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| AU781880B2 (en) | 1999-09-17 | 2005-06-16 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US20040171630A1 (en) | 2001-06-19 | 2004-09-02 | Yuntae Kim | Tyrosine kinase inhibitors |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| EP2256106B1 (en) | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| GB0317127D0 (en) * | 2003-07-22 | 2003-08-27 | Astex Technology Ltd | Pharmaceutical compounds |
| WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| WO2006050076A1 (en) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| BRPI0719122A2 (pt) * | 2006-08-24 | 2013-12-10 | Novartis Ag | Compostos orgânicos |
| WO2009110254A1 (ja) | 2008-03-04 | 2009-09-11 | 日本電気株式会社 | 電界効果トランジスタ及びその製造方法 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| SG172282A1 (en) | 2008-12-19 | 2011-07-28 | Hoffmann La Roche | Pyrimidin- 2 -ylamino derivatives and their use to treat inflammation |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| MX2012002641A (es) | 2009-09-10 | 2012-03-14 | Hoffmann La Roche | Inhibidores de cinasa janus (jak). |
| EP2569302A1 (en) | 2010-05-13 | 2013-03-20 | Amgen, Inc | Heteroaryloxyheterocyclyl compounds as pde10 inhibitors |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| JO3300B1 (ar) * | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| TW201444820A (zh) * | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| MX370588B (es) | 2013-08-30 | 2019-12-16 | Ptc Therapeutics Inc | Inhibidores de la bmi-1 de pirimidina sustituida. |
| WO2015058163A2 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| KR102379517B1 (ko) | 2013-12-30 | 2022-03-25 | 제넨테크, 인크. | 세린/트레오닌 키나아제 억제제 |
| MX358346B (es) | 2014-04-04 | 2018-08-15 | Syros Pharmaceuticals Inc | Inhibidores de la quinasa dependiente de ciclina 7 (cdk7). |
| WO2016014904A1 (en) | 2014-07-24 | 2016-01-28 | Beta Pharma, Inc. | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
| WO2016015604A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| MX385777B (es) | 2014-12-24 | 2025-03-04 | Lg Chemical Ltd | Derivado de biarilo como agonista de gpr120. |
| WO2016192630A1 (zh) | 2015-06-01 | 2016-12-08 | 中国科学院上海药物研究所 | 一类具有激酶抑制活性的化合物、制备方法和用途 |
| AU2016283105C1 (en) * | 2015-06-26 | 2023-02-02 | Dana-Farber Cancer Institute, Inc. | 4,6-pyrimidinylene derivatives and uses thereof |
| CN105111191B (zh) * | 2015-07-21 | 2018-06-08 | 上海皓元生物医药科技有限公司 | 一种用于合成cdk9抑制剂的关键中间体及其制备方法和用途 |
| CN105153119B (zh) * | 2015-09-11 | 2019-01-01 | 广州必贝特医药技术有限公司 | 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用 |
| CN106928216A (zh) | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | 具有erk激酶抑制活性的化合物、其制备方法和用途 |
| US10662186B2 (en) | 2015-12-31 | 2020-05-26 | Shanghai Pharmaceuticals Holding Co., Ltd. | Substituted pyrimidines as cyclin-dependent kinase inhibitors |
| TWI736578B (zh) | 2016-02-06 | 2021-08-21 | 大陸商上海複尚慧創醫藥研究有限公司 | 6-5元稠合唑環衍生物及其藥物組合物，以及作為藥物的應用 |
| SG11201900328WA (en) | 2016-07-13 | 2019-02-27 | Jason Marineau | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
| WO2019057123A1 (zh) | 2017-09-20 | 2019-03-28 | 杭州英创医药科技有限公司 | 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 |
| CN118286225A (zh) * | 2018-04-26 | 2024-07-05 | 辉瑞公司 | 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物 |
-
2019
- 2019-04-22 CN CN202410393724.0A patent/CN118286225A/zh active Pending
- 2019-04-22 LT LTEPPCT/IB2019/053314T patent/LT3784664T/lt unknown
- 2019-04-22 CA CA3098283A patent/CA3098283C/en active Active
- 2019-04-22 HU HUE19727502A patent/HUE070823T2/hu unknown
- 2019-04-22 DK DK19727502.7T patent/DK3784664T3/da active
- 2019-04-22 CU CU2020000070A patent/CU20200070A7/es unknown
- 2019-04-22 PE PE2020001635A patent/PE20201202A1/es unknown
- 2019-04-22 KR KR1020207033931A patent/KR102596598B1/ko active Active
- 2019-04-22 SI SI201930918T patent/SI3784664T1/sl unknown
- 2019-04-22 HR HRP20250254TT patent/HRP20250254T1/hr unknown
- 2019-04-22 UA UAA202006733A patent/UA126177C2/uk unknown
- 2019-04-22 EP EP19727502.7A patent/EP3784664B1/en active Active
- 2019-04-22 FI FIEP19727502.7T patent/FI3784664T3/fi active
- 2019-04-22 ES ES19727502T patent/ES3021205T3/es active Active
- 2019-04-22 GE GEAP201915475A patent/GEP20227433B/en unknown
- 2019-04-22 CN CN201980042382.5A patent/CN112313219B/zh active Active
- 2019-04-22 MX MX2020011294A patent/MX2020011294A/es unknown
- 2019-04-22 GE GEAP202215475A patent/GEAP202215475A/en unknown
- 2019-04-22 AU AU2019259653A patent/AU2019259653B2/en active Active
- 2019-04-22 MA MA52360A patent/MA52360B1/fr unknown
- 2019-04-22 JP JP2020560277A patent/JP7089061B2/ja active Active
- 2019-04-22 RS RS20250294A patent/RS66650B1/sr unknown
- 2019-04-22 BR BR112020021689-5A patent/BR112020021689B1/pt active IP Right Grant
- 2019-04-22 PT PT197275027T patent/PT3784664T/pt unknown
- 2019-04-22 CR CR20200503A patent/CR20200503A/es unknown
- 2019-04-22 WO PCT/IB2019/053314 patent/WO2019207463A1/en not_active Ceased
- 2019-04-22 MD MDE20210192T patent/MD3784664T2/ro unknown
- 2019-04-22 SG SG11202009992VA patent/SG11202009992VA/en unknown
- 2019-04-22 RU RU2020134811A patent/RU2762557C1/ru active
- 2019-04-22 KR KR1020237036862A patent/KR102661053B1/ko active Active
- 2019-04-22 PL PL19727502.7T patent/PL3784664T3/pl unknown
- 2019-04-23 TW TW108114112A patent/TWI740135B/zh active
- 2019-04-23 US US16/391,836 patent/US10766884B2/en active Active
- 2019-04-24 UY UY0001038196A patent/UY38196A/es not_active Application Discontinuation
- 2019-04-26 PY PY201901932509A patent/PY1932509A/es unknown
-
2020
- 2020-07-29 US US16/942,209 patent/US11220494B2/en active Active
- 2020-10-13 PH PH12020551692A patent/PH12020551692A1/en unknown
- 2020-10-15 IL IL278075A patent/IL278075B2/en unknown
- 2020-10-21 CO CONC2020/0013149A patent/CO2020013149A2/es unknown
- 2020-10-21 EC ECSENADI202067394A patent/ECSP20067394A/es unknown
- 2020-10-22 NI NI202000072A patent/NI202000072A/es unknown
- 2020-10-23 DO DO2020000191A patent/DOP2020000191A/es unknown
- 2020-10-23 CL CL2020002748A patent/CL2020002748A1/es unknown
- 2020-11-06 ZA ZA2020/06944A patent/ZA202006944B/en unknown
-
2021
- 2021-12-07 US US17/544,303 patent/US12378232B2/en active Active
-
2022
- 2022-06-09 JP JP2022093962A patent/JP2022120096A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202000072A (es) | Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina | |
| CL2019000368A1 (es) | Inhibidores de cdk2/4/6. | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
| MD4820B1 (ro) | Compuşi dihidroizochinolinonici substituiţi | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| UY40230A (es) | Macrociclos con grupos P2’ heterocíclicos como inhibidores del factor XIa y composiciones farmacéuticas que los comprenden | |
| JOP20190174B1 (ar) | مثبطات jak1 انتقائية | |
| MX388321B (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| CL2018000697A1 (es) | Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue. | |
| MX420195B (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| AR099867A1 (es) | Compuestos imidazobenzotiazolo fusionados | |
| CY1123185T1 (el) | Παραγωγα ινδολιου | |
| AR106958A1 (es) | Derivados de tetrahidrotriazolopirimidina útiles como inhibidores de hne | |
| CR20250037A (es) | Inhibidores de cinasa dependientes de ciclina (divisional 2020-0503) |